Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Min, Sang-Won, Chen, Xu, Tracy, Tara E, Li, Yaqiao, Zhou, Yungui, Wang, Chao, Shirakawa, Kotaro, Minami, S Sakura +14 more·2015·Nature Medicine

Cited by (518)

Items 201–300 of 518

  1. Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells
    Jürgen J. Heinisch, Roland Brandt · 2016 · Microbial Cell
  2. Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now?
    Tharmegan Tharmaratnam, Mina Magued Abdalla Iskandar, Tyler Tabobondung, I Tobbia, Prasaanthan Gopee‐Ramanan, Taylor A. Tabobondung · 2018 · Frontiers in Neurology
  3. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model
    Jesus J. Campagna, Patricia R. Spilman, Barbara M. Jagodzinska, Dongsheng Bai, Asa Hatami, Chunni Zhu, Tina V. Bilousova, Michael Jun, Chris Jean Elias, Johnny D. Pham et al. · 2018 · Scientific Reports
  4. CHIP-mediated hyperubiquitylation of tau promotes its self-assembly into the insoluble tau filaments
    Ji Hyeon Kim, Jeeyoung Lee, Won Hoon Choi, Seoyoung Park, Seo Hyeong Park, Jung Hoon Lee, Sang Min Lim, Ji Young Mun, Hyun‐Soo Cho, Dohyun Han et al. · 2021 · Chemical Science
  5. CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
    Heidi Olzscha, Oleg Fedorov, Benedikt Mathias Kessler, Stefan Knapp, Nicholas Barrie La Thangue · 2016 · Cell chemical biology
  6. Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases
    Yin Li, Zexu Li, Tan Jin, Zhan‐You Wang, Pu Zhao · 2017 · Journal of Alzheimer s Disease
  7. Sirtuin 3 (SIRT3) Pathways in Age-Related Cardiovascular and Neurodegenerative Diseases
    Ciprian Nicolae Silaghi, Marius Florin Farcas, Alexandra Marioara Craciun · 2021 · Biomedicines
  8. Post-translational modifications in neurodegeneration
    Alessandro Didonna, Federico Benetti · 2015 · AIMS Biophysics
  9. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington’s disease patients
    Peng Liu, Benjamin R. Smith, Eric S. Huang, Abhishek Mahesh, Jean Paul Vonsattel, Ashley J. Petersen, Rocío Gómez‐Pastor, Karen H. Ashe · 2019 · Acta Neuropathologica Communications
  10. Tau‐targeting nanoparticles for treatment of Alzheimer's disease
    Shreya Pawar, Mohd Ahmar Rauf, Hosam Gharib Abdelhady, Arun K. Iyer · 2024 · Exploration
  11. Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity
    Marianna Karina Gorsky, Sylvie Burnouf, Oyinkan Sofola-Adesakin, Jacqueline Dols, Hrvoje Augustin, Carina Marianne Weigelt, Sebastian Grönke, Linda Partridge · 2017 · Scientific Reports
  12. Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease
    Hasan A. M. M. Almansoub, Hui Ru Tang, Ying Wu, Ding‐Qi Wang, Yacoubou Abdoul Razak Mahaman, Na Wei, Yusra A. M. Almansob, Wei He, Dan Liu · 2018 · Journal of Alzheimer s Disease
  13. Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
    Kang, You Jung, Diep, Yen N., Tran, Minh, Cho, Hansang · 2020 · International Journal of Molecular Sciences
  14. The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization
    Archana Prasad, Vishwanath Sivalingam, Vidhya Bharathi, Amandeep Girdhar, Basant Kumar Patel · 2018 · Biochimie
  15. Neutral Charged Immunosensor Platform for Protein-based Biomarker Analysis with Enhanced Sensitivity
    Yifan Dai, Liang‐Yuan Chiu, Yinuo Chen, Shiyi Qin, Xiaowei Wu, Chung-Chiun Liu · 2018 · ACS Sensors
  16. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates
    Aiko Robert, Michael Schöll, Thomas Vogels · 2021 · International Journal of Molecular Sciences
  17. Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau–microtubule interactions and inhibits aggregation
    Yuxing Xia, Brach M. Bell, Benoit I. Giasson · 2021 · Scientific Reports
  18. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies
    Jesús Ávila, Noemí Pallas‐Bazarra, Marta Bolós, Carmen Laura Sayas, Félix Hernández · 2015 · Expert Opinion on Therapeutic Targets
  19. Sports-related brain injuries: connecting pathology to diagnosis
    James Pan, Ian David Connolly, Sean Dangelmajer, James R. Kintzing, Allen Lin Ho, Gerald Arthur Grant · 2016 · Neurosurgical FOCUS
  20. Progressive Supranuclear Palsy and Corticobasal Degeneration
    David G. Coughlin, Dennis W. Dickson, Keith A. Josephs, Irene Litvan · 2021 · Advances in experimental medicine and biology
  21. Alzheimer’s disease: phenotypic approaches using disease models and the targeting of tau protein
    Elisabetta Lauretti, Domenico Praticò · 2020 · Expert Opinion on Therapeutic Targets
  22. AMPK Ameliorates Tau Acetylation and Memory Impairment Through Sirt1
    Lin Wang, Fang-Xiao Shi, Na Li, Yun Cao, Ying Lei, Jian‐Zhi Wang, Qing Tian, Xinwen Zhou · 2020 · Molecular Neurobiology
  23. Tau suppresses microtubule-regulated pancreatic insulin secretion
    Salvatore P. Mangiafico, Qing‐zhang Tuo, Xiao-Lan Li, Yu Liu, Christian Haralambous, Xulong Ding, Scott Ayton, Qing Wang, D. Ross Laybutt, Jeng Yie Chan et al. · 2023 · Molecular Psychiatry
  24. The metamorphic nature of the Tau protein: dynamic flexibility comes at a cost
    Sabbagh, Jonathan J., Dickey, Chad A. · 2016 · Frontiers in Neuroscience
  25. A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation
    Deepa Ajit, Hanna Trzeciakiewicz, Jui‐Heng Tseng, Connor M. Wander, Youjun Chen, Aditi Ajit, Diamond P. King, Todd J. Cohen · 2019 · Journal of Biological Chemistry
  26. G-quadruplexes and associated proteins in aging and Alzheimer’s disease
    M. J. Vijay Kumar, Rodrigo Morales, Andrey S. Tsvetkov · 2023 · Frontiers in Aging
  27. Therapeutic Strategies for Restoring Tau Homeostasis
    Zapporah T. Young, Sue‐Ann Mok, Jason E. Gestwicki · 2017 · Cold Spring Harbor Perspectives in Medicine
  28. Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology
    Subha Kalyaanamoorthy, Stanley K. A. Opare, Xiaoxiao Xu, Aravindhan Ganesan, Praveen P. N. Rao · 2024 · Current Alzheimer Research
  29. Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis
    Jinwang Ye, Suyue Zhong, Huali Wan, Xing Guo, Xuanbao Yao, Qiong Liu, Liming Chen, Jian‐Zhi Wang, Shifeng Xiao · 2025 · Molecular Neurodegeneration
  30. Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications
    Yuqing Liu, Kun Zhu, Weijun Peng, Zhaoqian Liu, Xiaoyuan Mao · 2026 · Signal Transduction and Targeted Therapy
  31. Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins
    Leonid Breydo, Jennifer Redington, Vladimir Nikolaevich Uversky · 2016 · International review of cytology
  32. Military‐related risk factors for dementia
    Heather M. Snyder, Roxana Octavia Carare, Steven Trent DeKosky, Mony J. de Leon, Derek M. Dykxhoorn, Li Gan, Raquel C. Gardner, Sidney R. Hinds, Michael S. Jaffee, Bruce T. Lamb et al. · 2018 · Alzheimer s & Dementia
  33. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis
    Amir Zeb, Chanin Park, Shailima DV Rampogu, Minky Son, Gihwan Lee, Keun Woo Lee · 2018 · ACS Chemical Neuroscience
  34. Will Sirtuins Be Promising Therapeutic Targets for TBI and Associated Neurodegenerative Diseases?
    Qianjie Yang, Yunxiang Zhou, Yuting Sun, Yi Luo, Ye Shen, Anwen Shao · 2020 · Frontiers in Neuroscience
  35. Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
    Hai Yang, Jin‐Ping Li, Xiaoxiong Li, Linqiu Ma, Mingliang Hou, Huadong Zhou, Rui Zhou · 2022 · Frontiers in Molecular Neuroscience
  36. PTMD 2.0: an updated database of disease-associated post-translational modifications
    Xinhe Huang, Zihao Feng, Dan Liu, Yujie Gou, Miaomiao Chen, Dachao Tang, Cheng Han, Jianzhen Peng, Di Peng, Yu Xue · 2024 · Nucleic Acids Research
  37. Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures
    Xiaoxia Shen, Huan Li, Beiyu Zhang, Yunan Li, Zheying Zhu · 2025 · Cells
  38. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders
    Brian J. Spencer, Sven Brüschweiler, Marco Sealey‐Cardona, Edward M. Rockenstein, Anthony Adame, Jazmin B. Florio, Michael Mante, Ivy Trinh, Robert A. Rissman, Robert Konrat et al. · 2018 · Acta Neuropathologica
  39. Protein lysine acetylation and its role in different human pathologies: a proteomic approach
    Orlando Morales-Tarré, Ramiro Alonso-Bastida, Bolívar Arcos-Encarnación, Leonor Pérez‐Martínez, Sergio Encarnación‐Guevara · 2021 · Expert Review of Proteomics
  40. Sirtuins promote brain homeostasis, preventing Alzheimer’s disease through targeting neuroinflammation
    Mateusz Wątroba, Dariusz Szukiewicz · 2022 · Frontiers in Physiology
  41. The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells
    Cristina Di Primio, Valentina Quercioli, Giacomo Siano, Matteo Rovere, Branislav Kováčech, Michal Novák, Antonino Cattaneo · 2017 · Frontiers in Molecular Neuroscience
  42. Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer’s disease and related tauopathies
    Maryam Bazrgar, Pariya Khodabakhsh, Fatemeh Mohagheghi, Mercedes Prudencio, Abolhassan Ahmadiani · 2020 · Pharmacological Research
  43. Patchouli alcohol ameliorates the learning and memory impairments in an animal model of Alzheimer's disease via modulating SIRT1
    Qingqing Xu, Ziren Su, Zhen Jie Hu, Wen Yang, Yan‐Fang Xian, Zhi‐Xiu Lin · 2022 · Phytomedicine
  44. Tauroursodeoxycholic acid: a bile acid that may be used for the prevention and treatment of Alzheimer’s disease
    Honghu Song, Jiancheng Liu, Linjie Wang, Xiaomin Hu, Jiayu Li, Li Zhu, Rizhao Pang, Anren Zhang · 2024 · Frontiers in Neuroscience
  45. Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity
    Ramón Cacabelos, Olaia A. Martínez-Iglesias, Natalia Cacabelos, Iván Carrera, Lola Corzo, Vinogran Naidoo · 2024 · Life
  46. A Distinct Tau Code Controlled by HDAC6 is Linked to Tau Pathogenesis and the Neuronal Stress Response
    Jui‐Heng Tseng, Aditi Ajit, Zarin Tabassum, Niyati Patel, Xu Tian, Youjun Chen, Alex W. Prevatte, Karen Ling, Frank Rigo, Rick B. Meeker et al. · 2020 · Cell Reports
  47. Post-translational lysine ac(et)ylation in health, ageing and disease
    Anna‐Theresa Blasl, Sabrina Schulze, Chuan Qin, Leonie G. Graf, Robert Vogt, Michael Lammers · 2021 · Biological Chemistry
  48. Behavioural Functions and Cerebral Blood Flow in a P301S Tauopathy Mouse Model: A Time-Course Study
    Faraz Ahmad, Hannah Mein, Jing Hong Yu, Hu Zhang, Ping Liu · 2021 · International Journal of Molecular Sciences
  49. Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review
    Massimiliano Buoli, Marta Serati, Alice Caldiroli, Daniela Galimberti, Elio Angelo Scarpini, Alfredo Carlo Altamura · 2017 · Journal of Geriatric Psychiatry and Neurology
  50. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
    Giancarlo Logroscino, Bruno Pietro Imbimbo, Madia Lozupone, Rodolfo Sardone, Rosa Capozzo, Petronilla Battista, Chiara Zecca, Vittorio Dibello, Gianluigi Giannelli, Antonello Bellomo et al. · 2019 · Expert Opinion on Pharmacotherapy
  51. Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings
    Pallavi Duggal, Sidharth Mehan · 2019 · Journal of Alzheimer s Disease Reports
  52. Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280–acetylated tau in cell and mouse models
    Song, Ha-Lim, Kim, Na-Young, Park, Jaewan, Kim, Meong Il, Jeon, Yu-Na, Lee, Se-Jong, Cho, Kwangmin, Shim, Young-Lim, Lee, Kyoung-Hye, Mun, Yeon-Seon et al. · 2023 · Journal of Clinical Investigation
  53. Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
    Michael J. Ellis, Christiana Lekka, Katie L. Holden, Hanna Tulmin, Faheem Seedat, Darragh Patrick O'Brien, Shalinee Dhayal, Marie‐Louise Zeissler, Jakob Grunnet Knudsen, Benedikt Mathias Kessler et al. · 2024 · Acta Neuropathologica
  54. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design
    Dan Wang, Xianlong Huang, Lu Yan, Luo‐Qi Zhou, Yan Chang, Jinhu Wu, Zhengding Su, Yongqi Huang · 2021 · The Protein Journal
  55. SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy
    Xiaomin Yin, Yuanyuan Li, Xing Fan, Fang Huang, Yanyan Qiu, Chenhao Zhao, Zheng Zhou, Qun Gu, Liye Xia, Junze Bao et al. · 2022 · Molecular Psychiatry
  56. Progressive Supranuclear Palsy Syndrome: An Overview
    Eduardo Ichikawa-Escamilla, Rodrigo A Velasco-Martínez, Laura Virginia Adalid-Peralta · 2024 · IBRO Neuroscience Reports
  57. Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury
    C Bravo, Karen Krukowski, Sarah Barker, Chao Wang, Yaqiao Li, Li Fan, Edwin Vázquez‐Rosa, Min‐Kyoo Shin, Man Ying Wong, Louise D. McCullough et al. · 2024 · Molecular Neurodegeneration
  58. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice
    Armine Hovakimyan, Tatevik Antonyan, Sepideh Kiani Shabestari, Olga Svystun, Gor Chailyan, Morgan Coburn, William Carlen-Jones, Irina Petrushina, Jean Paul Chadarevian, Karen Zagorski et al. · 2019 · Scientific Reports
  59. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry
    Andrea Renee Kelley, Stephan B. H. Bach, George L. Perry · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  60. Epigenetic Modulation on Tau Phosphorylation in Alzheimer’s Disease
    Chao-Chao Yu, Tao Jiang, Aofei Yang, Yanjun Du, Miao Wu, Li-Hong Kong · 2019 · Neural Plasticity
  61. BRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method
    Chae‐Seok Lim, Xi Kang, Vincent R. Mirabella, Huaye Zhang, Qian Bu, Yoichi Araki, Elizabeth T. Hoang, Shi‐Qiang Wang, Ying Shen, Sukwoo Choi et al. · 2017 · Genes & Development
  62. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
    Sin Hui Neo, Bor Luen Tang · 2017 · Progress in molecular biology and translational science
  63. Sirtuin 3 Mediates Tau Deacetylation
    Shiping Li, Junxiang Yin, Megan Nielsen, Thomas G. Beach, Li Guo, Jiong Shi · 2019 · Journal of Alzheimer s Disease
  64. Resveratrol targeting tau proteins, amyloid‐beta aggregations, and their adverse effects: An updated review
    Milad Ashrafizadeh, Ali Zarrabi, Masoud Najafi, Saeed Samarghandian, Reza Mohammadinejad, Kwang Seok Ahn · 2020 · Phytotherapy Research
  65. Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds
    Huahua Shi, Yan Zhao · 2024 · International Journal of Molecular Sciences
  66. Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
    Adrianna Wysocka, Ewelina Pałasz, Marta Steczkowska, Grażyna Niewiadomska · 2020 · Current Alzheimer Research
  67. A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors
    Aliki Drakontaeidi, Eleni A. Pontiki · 2023 · Pharmaceuticals
  68. Elevated MeCP2 in Mice Causes Neurodegeneration Involving Tau Dysregulation and Excitotoxicity: Implications for the Understanding and Treatment of MeCP2 Triplication Syndrome
    Kristen R. Montgomery, Anto Sam Crosslee Louis Sam Titus, Lulu Wang, Santosh R. D’Mello · 2018 · Molecular Neurobiology
  69. Mechanistic insights into procyanidins as therapies for Alzheimer's disease: A review
    Wenli Ruan, Shuo-Heng Shen, Yang Xu, Na Ran, Heng Zhang · 2021 · Journal of Functional Foods
  70. Recent Tau-Targeted Clinical Strategies for the Treatment of Alzheimer's Disease
    Ha E Lee, Dami Lim, Jae Yeol Lee, Sang Min Lim, Ae Nim Pae · 2019 · Future Medicinal Chemistry
  71. Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
    Mohammed Alrouji, Mohammed S. Alshammari, Tasqeeruddin Syed, Anas Shamsi · 2025 · Antioxidants
  72. Targeting Tau to Treat Clinical Features of Huntington's Disease
    Maria Masnata, Shireen Salem, Aurélie de Rus Jacquet, Mehwish Anwer, Francesca Cicchetti · 2020 · Frontiers in Neurology
  73. Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer’s disease and related tauopathies
    Nikhil Dave, Austin S. Vural, Ignazio Stefano Piras, Wendy Winslow, Likith Surendra, Joanna K. Winstone, Thomas G. Beach, Matthew J. Huentelman, Ramón Velázquez · 2021 · Acta Neuropathologica
  74. Dysregulation of the SIRT1/OCT6 Axis Contributes to Environmental Stress-Induced Neural Induction Defects
    Guoping Li, Zeyidan Jiapaer, Rong Weng, Yi Hui, Wenwen Jia, Jiajie Xi, Guiying Wang, Songcheng Zhu, Xin Zhang, Dandan Feng et al. · 2017 · Stem Cell Reports
  75. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
    Ali Shoeibi, Nahid Olfati, Irene Litvan · 2018 · Expert Opinion on Investigational Drugs
  76. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies
    Simon McKenzie-Nickson, Jacky Chan, Keyla A. Perez, Lin Wai Hung, Lesley Cheng, Amelia Sedjahtera, Lydia Gunawan, Paul Anthony Adlard, David J. Hayne, Lachlan E. McInnes et al. · 2018 · ACS Chemical Neuroscience
  77. Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau
    Hyeanjeong Jeong, Seulgi Shin, Jun‐Seok Lee, Soo Hyun Lee, Ja‐Hyun Baik, Sungsu Lim, Yun Kyung Kim · 2019 · International Journal of Molecular Sciences
  78. Tau Pathology, Metal Dyshomeostasis and Repetitive Mild Traumatic Brain Injury: An Unexplored Link Paving the Way for Neurodegeneration
    Sydney M. A. Juan, Maria Daglas, Paul Anthony Adlard · 2022 · Journal of Neurotrauma
  79. Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau
    Dan Li, Lei Wang, Brandon F. Maziuk, Xudong Yao, Benjamin L. Wolozin, Yong Ku Cho · 2018 · Journal of Biological Chemistry
  80. Emerging role of Metformin in Alzheimer’s disease: A translational view
    Juvenal A. Ríos, Juan Carlos Bórquez, Juan Alejandro Godoy, Juan Manuel Zolezzi, María Cristina Furrianca, Nibaldo C. Inestrosa · 2024 · Ageing Research Reviews
  81. Insulin resistance in Alzheimer's disease: signalling mechanisms and therapeutics strategies
    Mini Dahiya, Monu Yadav, Chetan Goyal, Anil Kumar · 2025 · Inflammopharmacology
  82. Inhibitors of heat shock protein 70 (Hsp70) with enhanced metabolic stability reduce tau levels
    Hao Shao, Xiaokai Li, Shigenari Hayashi, Jeanette L. Bertron, Daniel M. C. Schwarz, Benjamin C. Tang, Jason E. Gestwicki · 2021 · Bioorganic & Medicinal Chemistry Letters
  83. TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy
    George A. Edwards, Caleb A. Wood, Yang He, Quynh Nguyen, Peter J. Kim, Ruben Gomez‐Gutierrez, Kyung-Won Park, Yong Xu, Cody Zurhellen, Ismael Al‐Ramahi et al. · 2024 · Acta Neuropathologica
  84. Tauopathies: Mechanisms and Therapeutic Strategies
    Chen‐Chen Tan, Xiao-Yan Zhang, Lan Tan, Jin‐Tai Yu · 2017 · Journal of Alzheimer s Disease
  85. Disease-modifying therapies for tauopathies: agents in the pipeline
    Francesco Panza, Bruno Pietro Imbimbo, Madia Lozupone, Antonio Greco, Davide Seripa, Giancarlo Logroscino, Antonio Daniele, Carlo Colosimo · 2019 · Expert Review of Neurotherapeutics
  86. Early Drug‐Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors
    Annissa J. Huhn, Anna S. Gardberg, Florence Poy, François Brucelle, Valérie Vivat, Nico R. Cantone, Gaurav K. Patel, Chirag Patel, Richard T. Cummings, Robert J. Sims et al. · 2020 · ChemMedChem
  87. Key Physicochemical and Biological Factors of the Phase Behavior of Tau
    Geewoo Nam, Yuxi Lin, Mi Hee Lim, Young‐Ho Lee · 2020 · Chem
  88. Targeting tau in Alzheimer’s and beyond: Insights into pathology and therapeutic strategies
    Sunidhi Singh, Sumaiya Khan, Mohammad Shahid, Meryam Sardar, Md. Imtaiyaz Hassan, Asimul Islam · 2024 · Ageing Research Reviews
  89. Reelin changes hippocampal learning in aging and Alzheimer’s disease
    Austin T. Marckx, Katja Fritschle, Laurent Calvier, Joachim Herz · 2021 · Behavioural Brain Research
  90. The Clinical Significance of Cerebrospinal Fluid Reticulon 4 (RTN4) Levels in the Differential Diagnosis of Neurodegenerative Diseases
    Agnieszka Kulczyńska‐Przybik, Maciej Dulewicz, Agnieszka Słowik, Renata Borawska, Alina Kułakowska, Jan Kochanowicz, Barbara Mroczko · 2021 · Journal of Clinical Medicine
  91. Cooperative effects of SIRT1 and SIRT2 on APP acetylation
    Na Li, Ning Bai, Xiong Zhao, Rong Cheng, Xuan Wu, Bo Jiang, Xiaoman Li, Mingli Xue, Hongde Xu, Qiqiang Guo et al. · 2023 · Aging Cell
  92. Targets, trials and tribulations in Alzheimer therapeutics
    Ruchita Gharat, Gargi Dixit, Mihir Khambete, Arati Prabhu · 2023 · European Journal of Pharmacology
  93. Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases
    Yi-Fang Wu, Biao Ma, Chang Yu Liu, Dangdang Li, Guangchao Sui · 2024 · International Journal of Molecular Sciences
  94. Immunoglobulin G-Based Steric Hindrance Assay for Protein Detection
    Yifan Dai, Wei Xu, Chung-Chiun Liu · 2019 · ACS Sensors
  95. Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma
    Xiaoting Liang, Xin Wang, Yaohui He, Yuanzhong Wu, Li Zhong, Wen Liu, Dan Liao, Tiebang Kang · 2020 · Theranostics
  96. Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives
    Dominika Przewodowska, Weronika Zofia Marzec, Natalia Madetko‐Alster · 2021 · Frontiers in Molecular Neuroscience
  97. Unraveling the Influence of K280 Acetylation on the Conformational Features of Tau Core Fragment: A Molecular Dynamics Simulation Study
    Yu Feng Zou, Lulu Guan · 2021 · Frontiers in Molecular Biosciences
  98. Dementia Therapy Targeting Tau
    Luc Buée · 2019 · Advances in experimental medicine and biology
  99. “Cascaded Rocket” Nanosystems with Spatiotemporal Separation for Triple‐Synergistic Therapy of Alzheimer's Disease
    Ruiyuan Liu, Jun Yang, Xinyu Qiu, Weihong Ji, Jie Shen, Yan Li, Zhiguo Lü, Yanyue Wu, Wenli Wang, Jing Wang et al. · 2022 · Advanced Healthcare Materials
  100. Tau–FG-nucleoporin98 interaction and impaired nucleocytoplasmic transport in Alzheimer’s disease
    Niharika Nag, Timir Tripathi · 2022 · Briefings in Functional Genomics